Lots of tech news, as always!
Introducing the t:slim X Insulin Pump with Basal-I Technology was announced by Tandem Corporation, 21 July 2018.
We’re thrilled to announce the t:slim X2 Insulin Pump with Basal-IQ Technology has been granted FDA approval. This latest release from Tandem Diabetes Care helps pump users take charge of diabetes management by predicting and helping prevent lows.
Benefits of the system include:
- The ability to predict low glucose levels 30 minutes ahead of time and suspend insulin delivery to help reduce the frequency and duration of low-glucose events. A pivotal study of Basal-IQ Technology showed a 31% relative reduction in time spent below 70 mg/dL when compared with a CGM-enabled pump without Basal-IQ Technology.
- Integration with the new Dexcom G6 Continuous Glucose Monitoring system, which delivers continuous glucose readings to the t:slim X2 Insulin Pump to aid users in making in treatment decisions without fingersticks for mealtime dosing or calibrations.
- FDA approval for automated insulin delivery for pump users as young as 6 years old.
- A simple-to-learn interface that operates without constant user input or the use of complicated modes. In a clinical study, 91% of participants found Basal-IQ Technology easy to use.
- Introducing the t:slim X2 Insulin Pump with Basal-IQ Technology
- Tandem unveils free software update for predictive glucose tracking and insulin delivery
Dexcom Acquires TypeZero Technologies announced by Dexcom, 22 August 2018. More hot news!
DexCom, Inc., the leader in continuous glucose monitoring for people with diabetes, announced today that it has acquired TypeZero Technologies, Inc. TypeZero’s offering includes the inControl diabetes management system, designed to provide personalized diabetes management solutions including technology to automatically adjust and regulate insulin delivery.
Dexcom, TypeZero and the University of Virginia have had a longstanding, productive relationship in developing important technologies for diabetes management, including inControl for integration with both automated insulin delivery (“AID”) and smart pens. The companies share a consistent vision to improve the lives of people with diabetes through innovation.
Read more: Dexcom Acquires TypeZero Technologies
Building a Better Insulin Infusion System was reported by Omar Ford on MDDIOnline.com 17 August 2018. All about Capillary Biomedical, developed in our backyard at UC Irvine in California.
Capillary Biomedical is looking to develop a safer more reliable and accurate insulin infusion device. The Irvine, CA-based company has closed on $2.9 million in a seed financing to help get its SteadiSet infusion set on the market.
“We’re testing [our device] in animals at Thomas Jefferson University and we’re now preparing for our first human clinical work and getting on to the commercialization pathway with the 510(k) clearance,” Paul Strasma CEO and Co-founder of Capillary Biomedical, told MD+DI. “We’re looking to be on the market in late 2019.”
The core cannula technology was developed by Jeffery Joseph at the Jefferson Artificial Pancreas Center of Thomas Jefferson University with grant funding from the National Institutes of Health and JDRF, the leading global organization funding Type 1 diabetes research.
- Building a Better Insulin Infusion System
- Capillary Biomedical
- Capillary Biomedical Closes $2.9 Million Series Seed Financing for Commercialization of Novel Insulin Infusion Technology
Medtronic revenues reported best quarterly performance in more than a decade, with nearly 100,000 users on the 670G alone. Strong sales in Europe for the 640G (similar technology as the Tandem Basal-IQ) … and 670G is coming to Europe in a few months.
The revolution that’s about to transform blood testing was reported by Abigail Klein Leichman on Israel21c.org, 13 August 2018. This is interesting!
- Engineering for All (EfA) is developing a handheld programmable device that performs automated blood analysis and diagnostics at the point of care.
- Sonorapy is developing a technology to replace standard diagnostic blood tests with a noninvasive soundwave diagnostic tool to detect pathogens (viruses or bacteria) from a single blood sample.
- Sight Diagnostics of Tel Aviv recently launched OLO, an AI-based blood diagnostics device that does lab-quality complete blood count (CBC) tests from finger prick samples at the point of care.
Read more: The revolution that’s about to transform blood testing
Sensors to Smartphones Bring Patent Wars to Diabetes Monitoring was reported by Susan Decker on Bloomberg.com, 11 August 2018. Enough to get your blood boiling? If you ever had a Deltec Cozmo, this will definitely hit home!
Since the early 1960’s, diabetics are benefiting from an explosion in technology and innovation, from under-the-skin sensors that eliminate the need for painful finger pricks, to smartphone alerts when glucose levels rise too high. But the technology, and its integration with mobile devices, has brought the types of lawsuits typically seen by Silicon Valley companies.
For glucose monitors alone, the number of published patent applications has grown steadily for a decade and has accelerated significantly since 2015, according to an analysis by the research firm Patinformatics. More than 880 patent applications related to glucose monitoring have been published so far this year, said Tony Trippe, managing director of the Dublin, Ohio-based company.
“Everybody in the market is realizing there’s an enormous opportunity there,” said Paul Desormeaux, a senior analyst with Toronto-based Decision Resources Group. “Other players are starting to come in, and there’s a lot of competition to make advanced products.”
Abbott Laboratories, Roche Holding AG, DexCom Inc. and Medtronic Plc are the top owners of patents, with San Diego-based medical device company DexCom having shown the highest rate of growth since 2015, Trippe said.
Read more: Sensors to Smartphones Bring Patent Wars to Diabetes Monitoring
Sight Diagnostics sounds a lot like Elizabeth Holmes. after reading that book, I will believe it when I see it.